David Raleighمشاهده پروفایل
دانشیار
David Raleigh, MD, PhD, is an Associate Professor and Physician-Scientist in the Department of Radiation Oncology at the University of California, San Francisco (UCSF), where he dedicates 80 % of his effort to laboratory research as a Principal Investigator in the UCSF Brain Tumor Center. He specializes in adult and pediatric brain tumors, focusing on developmental signaling pathways to uncover biomarkers and therapeutic targets for medulloblastoma, meningioma, and glioblastoma. Education & Training: University of California, Berkeley – B.A. (Honors) Molecular & Cell Biology and Cognitive Science (2000-2004) University of Chicago – Ph.D. Pathology (2007-2010) University of Chicago – M.D. (2005-2012) Kaiser Permanente Santa Clara – Intern, Internal Medicine (2012-2013) UCSF – Resident, Radiation Oncology (2013-2017) UCSF – Post-doctoral Fellow, Cancer Biology (2015-2017) Research Interests: Dr. Raleigh’s laboratory integrates biochemistry, molecular & cell biology, mouse genetics, genomics, bioinformatics, and pharmacology to decode developmental signaling cascades in brain tumors. His group discovered novel activators of oncogenic Hedgehog signaling in medulloblastoma and defined a FOXM1/WNT axis driving meningioma proliferation—work now serving as the basis for ongoing molecular therapy trials. Recent peer-reviewed output (2024-2025) reveals three major themes: (i) molecular & spatial atlases that refine risk stratification for meningioma and brain metastases; (ii) immune-microenvironment interrogations demonstrating IL-6-mediated immunosuppression and STING targeting opportunities; and (iii) therapeutic sensitization strategies employing CRISPRoff epigenetic editing, carbonic anhydrase inhibition, and DOTATATE-guided radiation planning. Honors & Awards: FASEB, Takeda, DDW Travel Awards Naomi Ragins Goldsmith Career Development Award UChicago Outstanding Graduate Student Oral Presentation UChicago Outstanding Performance in Radiation & Cellular Oncology Kaiser Permanente Teaching Award for Medical Student Education UCSF Resident Research Travel Award & RSNA Roentgen Award ASCO Top Young Investigator Awardee & ARS Young Oncologist Travel Grant Funding & Grants: NIH/NCI R01CA262311 (2021-2026) – “Understanding druggable drivers of meningioma tumorigenesis” (PI) NIH/NCI R01CA251221 (2021-2026) – “Mechanisms of Hedgehog signaling in glioblastoma” (PI) NIH/NCI K08CA212279 (2017-2022) – “Understanding How Ciliary Hedgehog Signaling Causes Medulloblastoma” (PI) Laboratory & Teams: Dr. Raleigh leads a multidisciplinary team within the UCSF Brain Tumor Center that collaborates with neurosurgery, neurology, bioengineering, and pharmaceutical partners. His group maintains active roles in multi-institutional consortia including the International Consortium on Meningiomas (ICOM) and cIMPACT-NOW, shaping global guidelines for molecular diagnostics and targeted trial design.










